Dr. Albert Chiou, MD
Dermatology (Dermatology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 386
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Harvard Medical School
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A131904 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 386
- Services billed
- 1,603
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 897 | 141 |
| Destruction of precancer skin growth, 1 growth | 222 | 162 |
| Established patient office or other outpatient visit, 30-39 minutes | 221 | 155 |
| Established patient office or other outpatient visit, 20-29 minutes | 201 | 164 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 104 | 103 |
| Biopsy of related skin growth, first growth | 80 | 69 |
| Destruction of skin growth, 1-14 growths | 59 | 53 |
| New patient office or other outpatient visit, 30-44 minutes | 37 | 37 |
| Injection into skin growth, 1-7 growths | 37 | 21 |
| Biopsy of related skin growth, each additional growth | 29 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Stanford, CA | 91 |
| Triamcinolone Acetonide Other prescribers in Stanford, CA | 55 |
| Clobetasol Propionate Other prescribers in Stanford, CA | 34 |
| Hydrocortisone Other prescribers in Stanford, CA | 33 |
| Fluocinonide Other prescribers in Stanford, CA | 32 |
| Metronidazole Other prescribers in Stanford, CA | 30 |
| Clindamycin Phosphate Other prescribers in Stanford, CA | 24 |
| Dupixent Syringe (dupilumab) Other prescribers in Stanford, CA | 20 |
| Mupirocin Other prescribers in Stanford, CA | 16 |
| Cosentyx Sensoready (2 Pens) (secukinumab) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 1 companies. The companies reported $72,728 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
AbbVie Inc. · Completed · NCT03569293 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc. - M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.